The Reality of Virtual Reality

Of course, Digital Pharma and the drug Virtua are fantasy. But the digital technologies highlighted in the fictional news story are available today.

Articles in this issue

over 25 years ago

Article

See No Evil

over 25 years ago

Article

Language, Layout, & Links: Creating Trustworthy Online Messages

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

The Reality of Virtual Reality

Articles in this issue

Related Content

Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

Focusing on Asset Acquisition Over Building a Single Platform Technology

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Trending on PharmExec

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

Focusing on Asset Acquisition Over Building a Single Platform Technology

M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration